Click the blue text above to follow Alzheimer’s disease for free now
University of California, San Diego, July 19 News
University of California San Diego, UCSD), Burke Neurological Institute (BNI), and Columbia University Irving Medical Center (CUIMC) The collaborative Alzheimer’s Disease Cooperative Study (ADCS), will provide 4,500 at the National Institutes of Health (NIH) and the National Institute on Aging (NIA) $10,000 funding to initiate a nationwide clinical trial to further investigate the synthetic version of thiamine (vitamin B1), benfotiamine, as a metabolic treatment for Alzheimer’s disease The therapeutic potential of the method.
This trial advances the ADCS’ mission of developing and testing therapies to enable those at risk or those experiencing symptoms of Alzheimer’s disease (AD). ADCS will coordinate a multicenter trial to assess whether high-dose benfotiamine benefits people with mild AD or AD-induced mild cognitive impairment (MCI).
This assay addresses a tissue defect in the thiamine-regulated metabolic pathway associated with AD. Previous work by Gary E. Gibson, Ph.D., professor of neuroscience and co-principal investigator in the Brain and Mind Institute at Weill Cornell Medicine, found that reduced glucose metabolism is associated with this reduction in thiamine dependence. related to this defect.
Dr.Gary E. Gibson
Experimental models suggest that increasing thiamine to very high levels with benfotiamine supplementation appears to prevent Alzheimer’s disease-like symptoms. For this study, starting in early 2023, ADCS will enroll approximately 400 patients at up to 50 U.S. clinical trial sites.
“We are delighted to receive this funding, which will allow benfotiamine testing to expand into clinical proof-of-concept, including in Adaptive Testing of Optimal Dose and Treatment Response in Clinical and Biomarker Measurements,” Howard Feldman, Ph.D., Dean of Alzheimer’s Research and Professor of Neuroscience, University of California, San Diego School of Medicine Say.
Dr. Howard Feldman
Benfosthiamine Research Participants were monitored over 18 months using a variety of measures, including cognitive tests and blood markers indicative of AD and MCI status and progression.
“At the Burke Institute of Neurology, we study the effect of thiamine (vitamin B1) on The impact of neurodegenerative disease has been more than 40 years old,” said Gibson, “This important grant will allow us to test this treatment on hundreds of Alzheimer’s patients in the United States . We are eager to begin this critical new phase of research.
“I’m particularly excited about this experiment because it will determine the dozens of years of research in relation to the treatment of Alzheimer’s disease.”
This trial highlights ADCS’ efforts to develop new interventional approaches. ADCS, in partnership with the University of Southern California, recently received a $50 million gift from the Epstein Family Foundation to support two projects: researching the use of gene therapy for AD, and >Penny Powder (P4P ) is designed to accelerate programs to test existing or repurposed medicines and natural products for treatment.
Benfotiamine is a good example of a P4P approach. If found to be beneficial, the treatment will be widely available and affordable.
Other educational and lifestyle interventions are being developed by ADCS . A study called HALT-AD is a pilot of healthy actions and lifestyles for Avoiding Dementia or Hispanos y el ALTo a la Demencia , is a bilingual, bicultural program that recruits community members into educational programs and discussion groups so they can learn more about dementia and take preventive measures.
The recently completed EXERT study, coordinated nationally by ADCS, is a Phase III clinical trial to test whether physical activity can slow the growth of 65- to 89-year-old adults Progression of mild memory loss and/or MCI. The findings will be presented at the Alzheimer’s Association International Conference in San Diego in late July.
“It is critical that ADCS help lead the search for new possibilities to prevent and treat dementia,” Feldman said. “All indicators suggest that we can make progress by implementing a broad research methodology.”
The benfotiamine research continues by Alzheimer’s Work funded by the Drug Discovery Foundation (ADDF).
ADDF co-founder and chief scientific officer Howard Fillit said, “It is great to see research that ADDF initially considered promising and supported in a pilot study to continue with the NIH. Funding from the National Institute on Aging. With improved biomarkers developed since the pilot, the next phase will provide a deeper understanding of benfotiamine’s role in the brain.”
University of California, San Diego, founded in 1960
Reference
p>
Source: University of California San Diego
Novel treatment approach to Alzheimer’s disease uses vitamin B1 derivative
https://ucsdnews.ucsd.edu/pressrelease/novel- treatment-approach-to-alzheimers-disease-uses-vitamin-b1-derivative
Disclaimer
The medical information on this official account is only provided and shared as an information resource, and is not used or relied upon for any diagnostic or therapeutic purpose. This information should not be used as a substitute for professional diagnosis or treatment. Please consult your doctor before making any medical decision or guidance regarding a specific medical condition.
Caring for parents, caring for Alzheimer’s disease